COMPARISON OF PEMETREXED PLUS CISPLATIN WITH OTHER FIRST-LINE DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A COMBINED ANALYSIS OF THREE PHASE 3 TRIALS

被引:0
|
作者
Treat, Joseph [1 ]
Scagliotti, Giorgio [2 ]
Peng, Guangbin [1 ]
Pohl, Gerhardt [1 ]
Obasaju, Coleman [1 ]
机构
[1] Eli Lilly & Co, Med, Indianapolis, IN USA
[2] Univ Turin, S Luigi Hosp, Dept Clin & Biol Sci, I-10124 Turin, Italy
关键词
NSCLC; Pemetrexed;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:S415 / S416
页数:2
相关论文
共 50 条
  • [1] Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials
    Treat, Joseph
    Scagliotti, Giorgio V.
    Peng, Guangbin
    Monberg, Matthew J.
    Obasaju, Coleman K.
    Socinski, Mark A.
    [J]. LUNG CANCER, 2012, 76 (02) : 222 - 227
  • [2] Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase III trials
    Treat, J.
    Scagliotti, G.
    Peng, G.
    Monberg, M. J.
    Obasaju, C. K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] FIRST LINE CHEMOTHERAPY WITH PEMETREXED PLUS CISPLATIN IN ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A COMPARISON OF TWO PHASE III TRIALS
    Scagliotti, Giorgio
    Gridelli, Cesare
    De Marinis, Filippo
    Thomas, Michael
    Dedui, Mircea
    Pujol, Jean-Louis
    Manegold, Christian
    Melemed, Symantha
    John, William
    Zimmermann, Annamaria H.
    Chouaki, Nadia
    Melemed, Allen
    Visseren-Grul, Carla
    Paz Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1160 - S1161
  • [4] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [5] PALLIATIVE RADIATION DURING PEMETREXED PLUS CISPLATIN FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PATIENT SAFETY IN THE JMDB AND PARAMOUNT TRIALS
    Scagliotti, G. V.
    Gridelli, C.
    de Marinis, F.
    Biesma, B.
    Reck, M.
    San Antonio, B.
    Zimmermann, A. H.
    Visseren-Grul, C.
    Chouaki, N.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S45 - S45
  • [6] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [7] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [8] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] EFFECTIVENESS OF FIRST-LINE PEMETREXED PLUS PLATINUM FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Brandao, M. D. R. A.
    Luis, M. S.
    Amaral, N. C.
    Cassiano Neves, M.
    Camacho, C.
    Rodrigues, A. C.
    Pousa, I.
    Oliveira, J.
    Azevedo, I.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [10] Meta-analysis of pemetrexed (P) plus gemcitabine (G) in first-line, advanced (adv) non-small cell lung cancer (NSCLC)
    Ye, Z.
    Treat, J. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)